Get started
Author

Mario Russo

OpenAlex ID: A5111636901
Differential expression of specific microRNA and their targets in acute myeloid leukemia
2010 · Giuseppe Cammarata, Luigi Augugliaro, et al. · American Journal of Hematology · 145
PDF
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL)
2010 · for the Gruppo Italiano per lo Studio dei Linfomi, Andrea Ferrario, et al. · Annals of Hematology · 12
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.
2010 · Paolo Vigneri, Fabio Stagno, et al. · Blood · 6
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib
2013 · Paolo G Vigneri, Fabio Stagno, et al. · Blood · 4
High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.
2012 · Paolo G Vigneri, Fabio Stagno, et al. · Blood · 4
High BCR-ABL/GUSIS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib
2015 · Paolo Vigneri, Fabio Stagno, et al. · Blood · 2
Front-Line Treatment of Low-Grade Non-Follicular Non-Hodgkin Lymphoma (Final Report of Gisl LL02 Trial).
2007 · Maria Goldaniga, Francesco Merli, et al. · Blood · 2
Frontline treatment with the combination fludarabine-cyclophosphamide in low-grade non-follicular non-Hodgkin lymphoma : a long term updating of GISL LL02 trial
2010 · Andrea Ferrario, Maria Goldaniga, et al.
Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report.
2009 · Paolo Vigneri, Fabio Stagno, et al. · Blood
Works count: 9
Citation count: 175
H-index: 4
I10-index: 2
Year
Topic
Type